Philip J. Mease

Stories

FDA approves ILUMYA for psoriatic arthritis, adding an in-office IL-23 option

Commenting clinician on the approval

On October 30, 2026, the Food and Drug Administration approved ILUMYA for adults with active psoriatic arthritis. The drug, tildrakizumab, had been cleared since 2018 only for plaque psoriasis, a skin condition.

Updated 1 hour ago

First TYK2 inhibitor reaches FDA decision for psoriatic arthritis

New Capabilities

As of May 2026: Active clinical researcher in psoriatic arthritis therapeutics

For most of the past decade, people with psoriatic arthritis who wanted a pill had one real choice: Janus kinase (JAK) inhibitors. The FDA slapped those drugs with its strongest safety warning in 2021, after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death.

Updated May 30